Impact of implementing common guidelines at different care levels in a healthcare area on the improvement of atrial fibrillation treatment;Impacto de la instauración de un protocolo común en los distintos niveles asistenciales de un área sanitaria para la mejora del tratamiento de la fibrilación auricular

Revista Espanola de Cardiologia

Volumn 60, Issue 4, 2007, Pages 392-403

  Coll Vinent, Blanca ^a   Pacheco, Gustavvo ^a   Junyent, Mireia ^a   Benito, Lluïsa ^a   Hoyo, Jordi ^a   García, Ana ^a   Calvo, Naiara ^a   Doltra, Adelina ^a   Miró, Òscar ^a   Sánchez, Miguel ^a   Monteagudo, Joan ^b   Mont, Lluís ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b Centro de Atención Primaria Les Corts   (Spain)

Author keywords

Adequacy treatment; Atrial fibrillation; Levels of health care; Treatment protocol

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN;

ADULT; AGED; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; EMBOLISM; FEMALE; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

EID: 34250004566     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13101643     Document Type: Article

References (24)

1. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98:476-84.
2. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age, distribution and gender of patients with atrial fibrillation. Arch Intern Med. 1995;155:469-73.
3. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 1982;306:1018-22.
4. Chug SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: Clinical implications. J Am Coll Cardiol. 2001;37:371-8.
5. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death. The Framingham Heart Study. Circulation. 1998;98:946-52.
6. Jenkins LS, Brodsky M, Schron E, Chung M, Rocco T Jr, Lader E, et al. Quality of life in atrial fibrillation: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149:112-20.
7. Valderrama AL, Dunbar SB, Mensah GA. Atrial fibrillation. Public health implications. Am J Prev Med. 2005;29 Suppl. 1:75-80.
8. Savalieva I, Camm AJ. Atrial fibrillation and heart failure: natural history and pharmacological treatment. Europace. 2004;5:S5-19.
9. Atrial fibrillation investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-57.
10. Almendral J, Martín E, Medina O, Peinado R, Pérez I, Ruiz R, et al. Guía de práctica clínica de la Sociedad Española de Cardiología en arritmias cardíacas. Rev Esp Cardiol. 2001;54:307-67.
11. Panel del Consenso del Grupo de Arritmias de la Sociedad Española de Medicina de Urgencias y Emergencias (SEMES) y la Sección de Electrofisiología de la Sociedad Española de Cardiología (SEC). Guías para el manejo de la fibrilación auricular en los servicios de urgencias hospitalarios. Emergencias. 2002; 14:243-61.
12. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines fort he management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines and policy conferences (Committee to Develop Guidelines fort he management of patients with atrial fibrillation). Circulation. 2001;104:2118-50.
13. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antitgrombotic therapy in atrial fibrillation. The seventh ACCP Conference on antithrombotic and thrombolitic therapy. Chest. 2004;126:S429-56.
14. Coll-Vinent B, Junyent M, Orús J, Villarroel C, Casademont J, Miró O, et al. Adecuación del tratamiento de la fibrilación auricular en los distintos niveles asistenciales de un área sanitaria. Med Clin (Barc). En prensa.
15. Romera I, De Dios R, García A, González Y, Lenza C, Salinero MA. Adecuación de la profilaxis tromboembólica en pacientes con fibrilación auricular crónica en 3 centros de atención primaria. Aten Primaria. 2004;33188-92.
16. Laguna P, Martín A, Del Arco C, Gargantilla P, and investigators of GEFAUR. Risk Factors fro stroke and thromboprophilaxis in atrial fibrillation: what happens in daily clinical practice? The GEFAUR-1 study. Ann Ernerg Med. 2004;44:3-11.
17. Mosquera Pérez I, Muñiz J, Freire E, García A, Castro-Beiras A. Grupo de trabajo del estudio INCARGAL. Uso de la anticoa-gulación al alta hospitalaria en pacientes con insuficiencia cardiaca y fibrilación auricular. Rev Esp Cardiol. 2003;56: 880-7.
18. Blanch P, Freixa R, Ibernón M, Delso J, Salas E, Sobrepera JL, et al. Utilización de anticoagulantes orales en pacientes con fibrilación auricular al alta hospitalaria en el año 2000. Rev Esp Cardiol. 2003;56:1057-63.
19. Waldo AL, Becker RC, Tapson VF, Colgan KJ, for the NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46:1729-36.
20. Zimetbaum P, Reynolds MR, Ho KKL, Gaziano Thomas, McDonald MJ, McClennen S, et al. Impact of a practice guideline for patients with atrial fibrillation on medical resource utilisation and costs. Am J Cardiol. 2003;92:677-81.
21. Ruiz M, Romo E, Franco M, Mesa D, Anguita M, López A, et al. Un protocolo prospectivo permite incrementar la utilización de anticoagulación oral en pacientes con fibrilación auricular crónica no valvular. Rev Esp Cardiol. 2003;56:971-7.
22. Martín D, Pedrero P, Martínez JA, González A, Hernando T, Herreros I. Prevención de la enfermedad tromboembólica en pacientes con fibrilación auricular crónica en atención primaria. Med Clin (Barc). 2004; 122:53-6.
23. Frieberg J, Gilason GH, Gadsboll N, Rasmussen JN, Rasmussen S, Abildstrom SZ, et al. Temporal trends in the prescription of vitamin K antagonists in patients with atrial fibrillation. J Int Med. 2006;259:173-8.
24. Nieulaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, et al. Atrial fibrillation management: a prospective survey in ESC member countries. The Euro Heart Survey on atrial fibrillation. Eur Heart J. 2005;26:2422-34.